The latest pharmacotherapy options for type 1 diabetes

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 1, 2014, Pages 37-49

  Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Acarbose; Adjunct therapy; Amylin; C peptide; GLP 1; Glucagon; IGF 1; SGLT2 inhibitors glucosuria; Type 1 diabetes

Indexed keywords

AMYLIN; AUTOANTIGEN; C PEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE OXIDASE; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; OXIDOREDUCTASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN 1; UNCLASSIFIED DRUG;

CELL FUNCTION; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG DELIVERY DEVICE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSURIA; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RESISTANCE; INSULIN TREATMENT; METABOLIC REGULATION; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 1; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS;

EID: 84890749286     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.855197     Document Type: Review

References (116)

1. Aanstoot HJ, Anderson BJ, Daneman D, et al. The global burden of youth diabetes: Perspectives and potential. Pediatr Diabetes 2007;8(Suppl 8):1-44
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
3. Bojestig M, Arnqvist HJ, Hermansson G, et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994;330:15-18
4. Wild D, Von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-11
5. Harjutsalo V, Forsblom C, Groop PH. Time trends in mortality in patients with type 1 diabetes: Nationwide population based cohort study. BMJ 2011;343:5364
6. Luczyn'ski W, Szypowska A, Glowin'ska-Olszewska B, Bossowski A. Overweight, obesity and features of metabolic syndrome in children with diabetes treated with insulin pump therapy. Eur J Pediatr 2011;170(7):891-8
7. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-15
8. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993;36:857-62
9. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:707-13
10. Oster-Jorgensen E, Pedersen SA, Larsen ML. The influence of induced hyperglycaemia on gastric emptying rate in healthy humans. Scand J Clin Lab Invest 1990;50:831-6
11. Lipp RW, Schnedl WJ, Hammer HF, et al. Evidence of accelerated gastric emptying in longstanding diabetic patients after ingestion of a semisolid meal. J Nucl Med 1997;38:814-18
12. Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent (diabetes mellitus. Diabetologia 1990;33:675-80
13. Madsbad S, Alberti KG, Binder CX, et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979;2:1257-9
14. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26:832
15. Wahren J, Ekberg K, Jornvall H. C-peptide is a bioactive peptide. Diabetologia 2007;50(3):503-9 . Good review up-dating on the support for the effect by C-peptide per s.e.
16. Jun HS. Regeneration of pancreatic beta cells. Front Biosci 2008;13:6170-82
17. Ludvigsson J. C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res Rev 2009;25(8):691-3
18. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protegé study): 1-year 871 results from a randomized, placebo-controlled trial. Lancet 2011;378(9790):487-97
19. Hagopian W, Ferry RJ Jr, Sherry N, et al. for the Prote'gé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: 2-year results from the randomized, placebo-controlled Protege trial. Diabetes 2013;
20. Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulindependent diabetes mellitus. N Engl J Med 1988;319(10):599-604
21. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361(22):2143-52
22. Dupre J, Stiller CR, Gent M, et al. Clinical trials of cyclosporin inIDDM. Diabetes Care 1988;11(Suppl 1):37-44
23. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297(14):1568-76
24. Ludvigsson J, Heding L, Lieden G, et al. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed (1983;286:176-8
25. Coutant R, Landais P, Rosilio M, et al. Low dose linomide in type I juvenile diabetes of recent onset: A randomised placebo-controlled double blind trial. Diabetologia 1998;41:1040-6
26. Ludvigsson J, Samuelsson U, Ernerudh J, et al. Photopheresis at onset of type 1 diabetes: A randomised, double blind, placebo controlled trial. Arch Dis Child 2001;85:149-54
27. Ludvigsson J, Samuelsson U, Johansson C, Stenhammar L. Treatment with antioxidants at onset of type 1 diabetes in children: A randomized, double-blind placebocontrolled study. Diabetes Metab Res Rev 2001;17:131-6
28. Ludvigsson J. Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity.Diabetologia. 2009;52(1):175-6
29. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 2001;358(9295):1749-53
30. Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359(18):1909-20
31. Ludvigsson J, Hjorth M, Cheramy M, et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: A randomised controlled trial. Diabetologia 2011;54(3):634-40
32. Wherrett DK, Bundy B, Becker DJ, et al. Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD (vaccine in patients with recent-onset type 1 diabetes: A randomised double-blind trial. Lancet 2011;378(9788):319-27
33. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012;366(5):433-42
34. Roep BO, Solvason N, Gottlieb PA, et al. BHT-3021 Investigators, Steinman L Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes. Sci Transl Med 2013;5(191):191
35. Walter M, Kaupper T, Adler K, et al. No effect of the 1a,25-dihydroxyvitamin D3 on b-cell residual function and insulin requirement in adults with newonset type 1 diabetes. Diabetes Care 2010;33(7):1443-8
36. Bizzarri C, Pitocco D, Napoli N, et al. No protective effect of calcitriol on b-cell function in recent-onset type 1 diabetes. The IMDIAB XIII trial. Diabetes Care 2010;33(9):1962-3
37. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381(9881):1905-15
38. Drucker DJ. Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17:161-71
39. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: Augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003;144:5145-8
40. Tourrel C, Bailbe D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-70
41. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-6
42. Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr 2008;153(4):547-53
43. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta- analysis. Diabetes Obes Metab 2009;11(4):372-8.649
44. Danne T, Datz N, Endahl L, et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: Results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008;9(6):554-60
45. Kalra S, Baruah MP, Niazi AK. Degludec: A novel basal insulin. Recent Pat Endocr Metab Immune Drug Discov 2012;6(1):18-23
46. Keating GM. Insulin degludec and insulin degludec/insulin aspart: A review of their use in the management of diabetes mellitus. Drugs 2013;73(6):575-93
47. Deiss D, Kordonouri O, Hartmann R, et al. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. Pediatr Diabetes 2007;8(3):157-62
48. Robertson KJ, Schoenle E, Gucev Z, et al. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007;24(1):27-34
49. Herwig J, Scholl-Schilling G, Bohles H. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin. J Pediatr Endocrinol Metab 2007;20(4):517-25
50. Hermansen K, Madsbad S, Perrild H, et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24(2):296-301
51. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009;52(9):1732-44
52. Sciacca L, Le Moli R, Vigneri R. Insulin analogs and cancer. Front Endocrinol (Lausanne) 2012;3:21
53. Danne T, Aman J, Schober E, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003;26(8):2359-64
54. Hanas SR, Carlsson S, Frid A, Ludvigsson J. Unchanged insulin absorption after 4 days' use of subcutaneous indwelling catheters for insulin injections. Diabetes Care 1997;20(4):487-90
55. Forst T, Hohberg C, Schondorf T, et al. Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. Diabetes Technol Ther 2009;2):87-92
56. Lasagna-Reeves CA, Clos AL, Midoro-Hiriuti T, et al. Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology 2010;151(10):4717-24
57. Zhang Y, Wu X, Meng L, et al. Thiolated Eudragit nanoparticles for oral insulin delivery: Preparation, characterization and in vivo evaluation. Int J Pharm 2012;436(1-2):341-50
58. Nordwall M, Ludvigsson J. Use of an insulin pen with memory is not enough to give better glycaemic control. Pediatric Diabetes 2011;12(Suppl 15):91
59. Adolfsson P, Veijola R, Huot C, et al. Safety and patient perception of an insulin pen with simple memory function for children and adolescents with type 1 diabetes-the REMIND study. Curr Med Res Opin 2012;28(9):1455-63
60. Olinder AL, Kernell A, Smide B. Missed bolus doses: Devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes 2009;10(2):142-8
61. Fuld K, Conrad B, Buckingham B, Wilson DM. Insulin pumps in young children. Diabetes Technol Ther 2010;12(Suppl 1):S67-71
62. Muller-Godeffroy E, Treichel S. German Working Group for Paediatric Pump Therapy. Investigation of quality of life and family burden issues during insulin pump therapy in children with type 1 diabetes mellitus-a large-scale multi-centre pilot study. Diabet Med 2009;26(5):493-501
63. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: A systematic review and meta-analysis. Ann Intern Med 2012;157(5):336-47
64. Pickup J. Insulin pumps. Int J Clin Pract Suppl 2011;170:16-19
65. Hanas R, Ludvigsson J. Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents. Pediatr Diabetes 2006;7(Suppl 4):32-8
66. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-76
67. Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011;34:2023-5
68. Danne T, Kordonouri O, Holder M, et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011;13:1-6
69. Hovorka R. Closed-loop insulin delivery: From bench to clinical practice. Nat Rev Endocrinol 2011;7:385-95
70. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: A phase 2 randomised crossover trial. Lancet 2010;375:743-51
71. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998;6(1):47-53
72. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 1992;105(4):1009-13
73. Iozzo P, Hallsten K, Oikonen V, et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabet Care 2003;26(7):2069-74
74. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333(9):550-4
75. Tiikkainen M, Hákkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53(8):2169-76
76. Meyer L, Guerci B. Metformin and insulin in type 1 diabetes: The first step. Diabetes Care 2003;26(5):1655-6
77. Hamilton J, Cummings E, Zdravkovic V, et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: A randomized controlled trial. Diabetes Care 2003;26(1):138-43
78. Sárnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: Randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003;149(4):323-9
79. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabet Care 2005;28(7):1562-7
80. Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism 2005;54(1):24-32
81. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338(13):867-72
82. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabet Care 2005;28(7):1547-54
83. Bhat R, Bhansali A, Bhadada S, Sialy R. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabet Res Clin Pract 2007;78(3):349-54
84. Stone ML, Walker JL, Chisholm D, et al. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: A randomized-controlled trial. Pediatr Diabet 2008;9(4 Pt 1):326-34
85. Ekberg K, Brismar T, Johansson BL, et al. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 2003;52:536-41
86. Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabet Care 2007;30:71-6
87. Johansson BL, Borg K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000;17:181-9
88. Bayne ML, Applebaum J, Chicchi GG, et al. The roles of tyrosines 24, 31, and 60 in the high-affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor. J Biol Chem 1990;265:15648
89. Clemmons DR, Dehoff MH, Busby WH, et al. Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs. Endocrinology 1992;131:890
90. Isley WL, Underwood LE, Clemmons DR. Dietary components that regulate serum somatomedin-C concentrations in humans. J Clin Invest 1983;71:175-82
91. Phillips LS, Pao CI, Villafuerte BC. Molecular regulation of insulin-like growth factor-I and its principal binding protein. IGFBP-3 Prog Nucleic Acid Res Mol Biol 1998;195-65
92. Henry RR, Abrams L, Nikoulina S, et al. Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Diabetes 1995;44:936-42
93. Maes M, Ketelslegers JM, Underwood LE. Low circulating somatomedin-C/insulin-like growth factor I in insulin-dependent diabetes and malnutrition: Growth hormone receptor and post-receptor defects. Acta Endocrinol Suppl 1986;279:86-92
94. Quattrin T, Thrailkill K, Baker L, et al. Improvement in HbA1c without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin. rhIGF-I in IDDM Study Group. J Pediatr Endocrinol Metab 2001;14.267-77
95. Acerini CL, Patton CM, Savage MO, et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997;350(9086):1199-204
96. Edelman SV, Caballero L. Amylin replacement therapy in patients with type 1 diabetes. Diabet Educ 2006;32:119S-27S
97. Want L. Use of pramlintide: The patient's perspective. Diabet Educ 2006;32:111S-8S
98. Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes. Pediatr Res 2007;62:746-9
99. Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998;41:577-83
100. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002;51:636-41
101. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabet Care 2006;29:2189-95
102. Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: A concise review, with emphasis on studies in humans. Regul Pept 2005;128:149-57
103. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992;130:159-66
104. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-96
105. Imeryuz N, Yegen BC, Bozkurt A, et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997;273:G920-7
106. Dupre J, Behme MT, Hramiak IM, et al. TJ Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995;44:626-30
107. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36 (amide in type I diabetic patients. Diabet Care 1996;19:580-6
108. Porksen S, Nielsen LB, Kaas A, et al. Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab 2007;92:2910-16
109. Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89:3469-73
110. Campbell SC, Macfarlane WM. Regulation of the pdx1 gene promoter in pancreatic beta-cells. Biochem Biophys Res Commun 2002;299:277-84
111. Li Y, Cao X, Li LX, et al. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005;54:482-91
112. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-6
113. Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabet Care 2000;23(8):1162-7
114. Laube H. Acarbose: An update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002;22(3):141-56
115. Chao EC. A paradigm shift in diabetes therapy- -dapagliflozin and other SGLT2 inhibitors. Discov Med 2011;11(58):255-63
116. Ludvigsson J. Insulin, love and care. Hormone Res 1989;31:204-9